Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$4.57 +1.3%	$5.31	$1.38 ▼ $7.34	$145.62M	1.62	824,157 shs	356,481 shs
EBS Emergent Biosolutions	$9.30 +0.5%	$7.11	$4.02 ▼ $12.73	$496.00M	1.97	1.25 million shs	819,122 shs
MYGN Myriad Genetics	$5.83 +5.4%	$5.12	$3.76 ▼ $29.30	$542.45M	1.89	1.75 million shs	988,315 shs
VSTM Verastem	$8.63 +3.7%	$5.67	$2.34 ▼ $9.10	$531.13M	0.83	1.80 million shs	2.88 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	-0.44%	-0.66%	-25.94%	+19.00%	-8.89%
EBS Emergent Biosolutions	+0.71%	+5.25%	+33.15%	+42.66%	-4.25%
MYGN Myriad Genetics	+0.36%	-5.79%	+24.27%	+40.71%	-79.99%
VSTM Verastem	+6.80%	+3.74%	+63.14%	+11.23%	+239.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGEN Agenus	3.9898 of 5 stars	3.3	2.0	4.6	2.4	1.7	0.6
EBS Emergent Biosolutions	4.6667 of 5 stars	3.5	1.0	4.6	3.1	2.5	2.5
MYGN Myriad Genetics	3.5592 of 5 stars	3.1	2.0	4.1	2.3	1.7	0.0
VSTM Verastem	3.1295 of 5 stars	3.4	3.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.50	Moderate Buy	$15.50	239.17% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	54.17% Upside
MYGN Myriad Genetics	2.21	Hold	$12.45	113.63% Upside
VSTM Verastem	2.89	Moderate Buy	$13.29	53.95% Upside

Current Analyst Ratings Breakdown

Latest AGEN, MYGN, VSTM, and EBS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	AGEN Agenus	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/12/2025	VSTM Verastem	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $13.00
6/25/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$16.00 ➝ $12.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$101.71M	1.43	N/A	N/A	($10.55) per share	-0.43
EBS Emergent Biosolutions	$812.50M	0.61	$1.94 per share	4.78	$10.05 per share	0.93
MYGN Myriad Genetics	$832.90M	0.65	$1.06 per share	5.51	$4.17 per share	1.40
VSTM Verastem	$2.14M	248.54	N/A	N/A	$0.59 per share	14.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	-$227.21M	-$7.15	N/A	N/A	N/A	-167.52%	N/A	-81.04%	N/A
EBS Emergent Biosolutions	-$190.60M	$2.45	3.79	4.49	N/A	16.38%	24.63%	8.97%	11/5/2025 (Estimated)
MYGN Myriad Genetics	-$127.30M	-$4.28	N/A	N/A	N/A	-47.45%	-5.17%	-3.44%	11/6/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.28	N/A	N/A	N/A	N/A	-2,003.62%	-119.85%	11/5/2025 (Estimated)

Latest AGEN, MYGN, VSTM, and EBS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AGEN Agenus	-$0.78	-$1.00	-$0.22	-$1.00	$49.71 million	$25.70 million
8/7/2025	Q2 2025	VSTM Verastem	-$0.64	-$0.39	+$0.25	-$0.39	$6.01 million	$2.14 million
8/6/2025	Q2 2025	EBS Emergent Biosolutions	-$0.26	$0.16	+$0.42	-$0.22	$148.55 million	$140.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.06	0.06
EBS Emergent Biosolutions	1.25	5.66	3.00
MYGN Myriad Genetics	N/A	1.42	1.28
VSTM Verastem	2.06	3.46	3.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
EBS Emergent Biosolutions	78.40%
MYGN Myriad Genetics	99.02%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	5.50%
EBS Emergent Biosolutions	1.20%
MYGN Myriad Genetics	2.40%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	440	31.86 million	30.11 million	Optionable
EBS Emergent Biosolutions	2,420	53.35 million	52.71 million	Optionable
MYGN Myriad Genetics	2,700	93.05 million	90.81 million	Optionable
VSTM Verastem	50	61.55 million	60.25 million	Optionable

AGEN, MYGN, VSTM, and EBS Headlines

Recent News About These Companies

Balyasny Asset Management L.P. Increases Stake in Verastem Inc

August 20 at 9:11 PM | gurufocus.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $13.29

August 20 at 2:11 AM | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 18 at 2:28 AM | marketbeat.com

Zacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 17, 2025 | marketbeat.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | insidermonkey.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | finance.yahoo.com

Verastem price target lowered to $14 from $16 at Mizuho

August 15, 2025 | msn.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results

August 14, 2025 | za.investing.com

Verastem Unveils Promising VS-7375 Study Results

August 14, 2025 | msn.com

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

August 13, 2025 | businesswire.com

Verastem Inc. Earnings Call: Positive Outlook with Key Achievements

August 13, 2025 | msn.com

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 11, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Releases Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Price Target Raised to $13.00

August 10, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Given New $13.00 Price Target at Royal Bank Of Canada

August 10, 2025 | americanbankingnews.com

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 8, 2025 | seekingalpha.com

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline

August 8, 2025 | msn.com

RBC Capital Raises Verastem (VSTM) Price Target to $13. ...

August 8, 2025 | gurufocus.com

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

August 8, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AGEN, MYGN, VSTM, and EBS Company Descriptions

Agenus NASDAQ:AGEN

$4.57 +0.06 (+1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$4.58 +0.01 (+0.22%)

As of 04:38 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Emergent Biosolutions NYSE:EBS

$9.30 +0.05 (+0.51%)

Closing price 03:59 PM Eastern

Extended Trading

$9.31 +0.02 (+0.18%)

As of 05:14 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Myriad Genetics NASDAQ:MYGN

$5.83 +0.30 (+5.42%)

Closing price 04:00 PM Eastern

Extended Trading

$5.71 -0.12 (-2.04%)

As of 05:02 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Verastem NASDAQ:VSTM

$8.63 +0.31 (+3.73%)

Closing price 04:00 PM Eastern

Extended Trading

$8.65 +0.02 (+0.23%)

As of 05:08 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time